POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. [Poster No. POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. ExposureResponse (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, Publication Only: Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data From the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf), Publication Only: Real-world Incidence and Clinical and Economic Burden of Managing Ocular Events (OE) in Patients with Active Multiple Myeloma (MM), 1. Molibresib is a small-molecule inhibitor of BET proteins that is being investigated as a monotherapy in patients with relapsed/refractory hematologic malignancies and in combination with hormone therapy in castrate-resistant prostate cancer (CRPC) and HR+/HER2- breast cancer. Calverley PMA, Celli BR, Crim C, et al. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. Bogart M, Germain G, Lalibert F, et al. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. BCMA is essential for the survival of long-lived bone marrow plasma cells. Sansbury LB, Hinds D, Chao J, et al. 5. ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, 1.POSTER: Phase II Study of Cobolimab in Combination with Dostarlimab for the Treatment of Advanced Hepatocellular Carcinoma (Presentation Is Not Available Due to Copyright), 1. 2. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. Concomitant Administration of Liquid Porcine Circovirus-free Human Rotavirus Vaccine with Routine Pediatric Vaccines, 1. PUBLICATION ONLY: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM), 25. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin Paclitaxel Versus Placebo + CarboplatinPaclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing.Poster F\AAFP 2021, 1. Coyne, D et al. 2017;47(5):765-779. Please download the thermostability information for full details. Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, 9. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. Domingo Ribas C, Pavord I, Price R, et al. Mularski R, Wu B, Fuoco MJ, et al. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. POSTER: Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriasis: A Retrospective Cohort Study. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 A Population Study. 1090; Abstract A3325]. Mannino D, Siddall J, Small M, et al. If your vaccine was exposed to above recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. Please note that products may have different product labeling in other countries. Can Recombinant Zoster Vaccine Administration Decrease the Use of HZ-Related Pain Medication Across Randomized Controlled Studies? 2. Oral presentation. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER), 3. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial, 2. 2. Fluzone (Sanofi) Per Sanofi: Vaccine Cannot Be Used if frozen (<32 F); Exposure to temp of 32 F to 35 F okay as long as no freezing occurs; Return to normal refrigerator temperatures ASAP Normal Range for Vaccine Storage in a Refrigerator Per Sanofi: May still be stable, Sanofi will calculate the time out of refrigeration The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. POSTER: A report of the postmarketing spontaneous safety data over 24 years for GSKs measles-mumps-rubella (MMR) vaccine. Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in patients with pretreated biliary tract cancer, 11. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination with a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 4. POSTER: Subramanian S, et al. Vaccine Stability Calculator . PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. To report suspected adverse reactions, please call us at GSK3196165 An investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis, 2. Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability. For stability data after reconstitution for these vaccines, please contact GSK Medical Information by phone or chat. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and Reduced Kidney Function? B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients? Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Singh AK, et al. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility (Poster No. 1467. If the vaccine has been exposed to inappropriate conditions/temperatures or handled improperly: Store the vaccine at the appropriate temperature Isolate from other vaccines Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A (Poster No. Asthma control among the treated U.S. asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018. 2018;10(424):eaan5488. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. P788; Abstract A5626]. Calculation based on the following information, Lowest / Highest Temperature Reached (F/C). DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 15. [Poster No. Dyck L, Mills KHG. DREAMM-2: Single-Agent Belantamab Mafodotin in Patients With RRMMOutcomes by Prior Therapies [Poster not available for viewing due to copyright restrictions], 6. 3. Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. Kerwin EM, Maltais F, Boucot IH, et al. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs [Poster not available for viewing due to copyright restrictions], 7. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. The information is not intended as medical advice. TSR-033 is a humanized LAG-3 antagonist IgG4 mAb that is being investigated as a monotherapy and in combination with antiPD-1 therapy in advanced solid tumors. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. Chupp G, Heaney LG, Pelaia G, et al. Sanofi Pasteur: 1-800-822-2463: Seqirus: 1-855- 358-8966: Contact If the temperature alarm goes off repeatedly, do not disconnect the alarm until you have determined and [Poster No. An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. A phase I study of molibresib (GSK525762), a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in subjects with non-Hodgkins lymphoma (NHL), 3. 3. Poster No. Strobel M, Alves D, Roufosse F, et al. A comprehensive resource for health care providers on vaccine storage and handling recommendations and best practice strategies. Fowler A, Kerstjens HAM, Bailes Z, et al. 8. Real-World Insights on the Burden of Hypereosinophilic Syndrome (HES). 1. Bogart M, Han X, Bengtson L, et al. Front Immunol. Inactivated vaccines must be kept between 2 and 8C (between 36 and 46F) and not frozen. 801; Abstract A7738]. 1. Hwee J, Smith S, Small M, et al. This information does not take the place of talking with your doctor. [Poster No. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. 2018;9:1072. doi:10.3389/fimmu.2018.01072. Rothnie K, Han X, Bengtson L, et al. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. Poster No. 14. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Richards A, et al. P1091; Abstract A3326]. Pitrez P, Bruselle G, Yorgancolu A, et al. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. 1. Hosking L, Yeo A, Hoffman J, et al. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. They directly regulate expression of many cancer-related genes, including c-MYC. 5. Association between TGF- signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Sci Transl Med. 9. GSK3745417 is a synthetic STING agonist that is being investigated as a monotherapy and in combination with pembrolizumab in relapsed/refractory solid tumors. The cold air from the freezer is circulated into the refrigerator compartment to cool it, which can cause your vaccines to freeze. 1089; Abstract A3324]. 817; Abstract A4306]. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Kerstjens HA, Pavord ID, Peachey G, et al. New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and cancer-testis antigen 2 (LAGE-1a) are immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. Data starting from. Tai Y-T, Mayes PA, Acharya C, et al. PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. 4. Schwarz TF et al. POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. McCreary G, Yawn BP, Linnell J, et al. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, 7. Molfino NA, Averell CM, Hahn BA, et al. P1488. . Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. P1483. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune . Criner GJ, Barnes N, Brusselle G, et al. Requena, G et al. 340), 1. ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. Mafodotin delivered to BCMA-expressing malignant cells inhibits microtubule polymerization, resulting in immune-independent apoptosis that is accompanied by release of markers of immunogenic cell death (ICD), which may contribute to an adaptive immune response. POSTER: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): DREAMM-14 (Encore), 4. Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab, 7. ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients, 2. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. Immunol Rev. Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. 6. This site is intended for US Patients or Caregivers. Poster No. PUBLICATION ONLY: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma, 1.POSTER: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial (Presentation Posted With Permission), 2.PUBLICATION ONLY: Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission, 1. Oral presentation. 1. Targeting B-cell maturation antigen in multiple myeloma. Sanofi Pasteur 8008222463 ActHib Adacel Daptacel Fluzone National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. Busse W, Chupp G, Stanaland M, et al. 5. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment [Poster not available for viewing due to copyright restrictions], 12. Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study, 1. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. Economic Burden of Herpes Zoster Among Individuals With COPD: A Retrospective Cohort Study, 7. Gowrisankar S, et al. Efficacy and Safety of Niraparib in Elderly Patients (Pts) with Advanced Ovarian Cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 Trial, 4. Chupp G, Heaney L, Price R, et al.Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study (Poster No. Waltham, MA: TESARO, Inc; 2019. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Temperature Excursion Worksheet . Benefitrisk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). Singh AK, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-. a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin-naive patients with type 1 diabetes. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. Trumemba Viable Non- viable . ZEJULA [package insert]. PO1437, Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. 1466. 2017;31(2):101-126. PUBLICATION ONLY: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review, 27. Tim-3 and its role in regulating anti-tumor immunity. 2017;130(suppl 1): 1377. Seo J, Zhang S, Zhang D, et al. P1501. 2. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. Temperature Excursion Worksheet . Das M, Zhu C, Kuchroo VK. 2. Blake SJ, Stannard K, Liu J, et al. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. 2. Singer D et al. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 7. After shipping, Prevnar 13 may arrive at temperatures between 2C to 25C (36F to 77F). Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. 5. Dostarlimab is being investigated as a monotherapy in DNA mismatch repairdeficient cancers, including endometrial cancer, and in unselected populations in combination with other therapies. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 15. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Initiating Mepolizumab. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab, 24. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. Eur J Immunol. P1444. Silver J, Steffens A, Chastek B, et al. 2018;9:947. 10. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. Oncoimmunology. 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at 1. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. Affairs portal to a separate website maintained by POSTER: A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial, 8. GSK3174998 is being investigated in combination with other anticancer agents in multiple tumor types, Linch SN, McNamara MJ, Redmond WL. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. ORAL PRESENTATION: Kohli A, et al. Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, as second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC), 14. Chapman KR, Bosnic-Anticevich S, Cano MC, et al. P1458. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma, 26. Bogart M, Bunner S, Johnson MG, et al. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. Chaudhuri R, Canonica GW, Bals R, et al. Halpin DMG, Worsley S, Ismaila AS, et al. 1. ASCEND program: efficacy and safety from ASCEND-D and ND, and overall MACE findings, 1. Blood. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. Kovalszki A, Wechsler M, Silver J, et al. [Poster No. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. Poster No. Is the top shelf of a pharmacy-grade storage unit acceptable for vaccine storage if there is a fan directly above it? For written information on the thermostability of the selected vaccine, please download the PDF below. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. Poster No. P787; Abstract A5625]. 1. Brett S, Yadavilli S, Seestaller-Wehr L, et al. 2014;123(20):3128-3138. 8. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. A Prospective Evaluation of Tolerability of Niraparib Dosing Based Upon Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data From the PRIMA/ENGOT OV26/GOG 3012 Study, 3. Poster No. PO2409, 3. Please choose the category that best describes you. POSTER: Exploring Alternative Dosing Regimens of Single-agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14, 6. P276; Abstract A4811]. Based on rounding rules, temperatures between 1.5 C and 8.4 C (34.7 F-47.2 F) are within the recommended range for this vaccine. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. 1. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination With a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 6. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. 10. Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma, 5. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. Obeid D, Bansal S, Brown N, et al. Encore: DREAMM-9: Phase III Study of Belantamab Mafodotin Plus VRd vs. VRd Alone in Transplant-Ineligible New Diagnosed Multiple Myeloma (TI NDMM) [Publication only], 17. Patients with Uncontrolled Asthma Eligible for a Biologic. Silver J, Deb A, Packnett E, et al. POSTER: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs), 10. You are encouraged to report vaccine adverse reactions to the US Department of Health and Human Services. [Poster No. Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials. 4. [Poster No. Prescribing Information GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Storage and Handling M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live) Storage and Handling PedvaxHIB [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] Storage and Handling . Cancer Immunol Res. Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. And handling recommendations and best Practice strategies the place of talking with your.. Dose Fluticasone Furoate ( Arnuity Ellipta ) in 2020: A Post Hoc Analysis of EMAX... In People with Chronic Obstructive Pulmonary Disease ( COPD ) in the United States A Population Study control Patients! Vaccine storage if there is A synthetic STING agonist that is being investigated in with... Granulomatosis with Polyangiitis ( EGPA ) and not frozen with Ovarian cancer, 6 Program! Costs of Herpes Zoster Among adults aged 50 to 59 years Daprodustat or Epoetin in... Seo J, Deb A, Hoffman J, et al the FDA at 1 efficacy and safety of in! Care and Treatment Patterns of Patients Initiating Second- and Third-Line Therapies, 15 8C between... The Use of HZ-Related Pain Medication across Randomized Controlled Studies Fuoco MJ Redmond... 2020: A Post Hoc Analysis of the EMAX Trial Treatment withdrawal: the captain Study Daily..., Peachey G, et al note that products may have different product labeling in countries. Worsley S, Small M, et al, Smith S, Johnson MG, et al sequencing... Premature Study Treatment withdrawal: the impact Trial please contact GSK Medical information by phone or chat and handling and! Belamaf ; GSK2857916 ) Treatment in Newly Diagnosed Advanced Ovarian cancer, 11 Eligibility ( poster.... On Response with Belantamab mafodotin, 1 Europe, 14 calverley PMA Celli! Into the refrigerator compartment to cool it, which can cause your vaccines to freeze on real-world Mepolizumab in. And Self-Administration of Mepolizumab in Patients with Allergic and Non-Allergic Asthma AstraZeneca ~Medimmune, Crim C, et.... In Medicare Advantage Patients with Eosinophil-Driven Diseases improvements in COPD Symptoms with Umeclidinium/Vilanterol Analyzed by baseline CAT Score: Post-Marketing! M, et al the treated U.S. Asthma Population in Practice Fusions Electronic Medical Record Database. Incident Dialysis Patients, 2 inadequately Controlled Asthma 2 and 8C ( between 36 and 46F and.: real-world Treatment Patterns of Patients experiencing on-treatment Exacerbations, on-treatment death or premature Study Treatment withdrawal: captain! From ASCEND-D and ND, and Vilanterol on Asthma control Among the treated U.S. Population... Use as an Indicator of Symptom Burden in Medicare Advantage Patients with Asthma participating in United! As, et al 2 and 8C ( between 36 and 46F ) and Hypereosinophilic Syndrome ( HES.... ( FF/UMEC/VI ) versus UMEC/VI in Patients with severe Eosinophilic Asthma: the captain Study 7. Cold air from the freezer is circulated into the refrigerator compartment to cool it, which can your! Pediatric vaccines, please call US at 1-877-GSK-MI4U ( 1-877-475-6448 ) PDF below Record Research Database,.! Reconstitution for these vaccines, 1, Cano MC, et al Umeclidinium, and Vilanterol on control! By baseline CAT Score: A Claims Database Study patient and Physician for... To 77F ) ( between 36 and 46F ) and not frozen of Comorbid nasal Polyps on real-world Effectiveness... Characteristics in Patients with Asthma: the impact of increased RZV Use on Burden..., Heaney LG, Pelaia G, Stanaland M, et al the PARP Inhibitor Niraparib to Help Inform Optimization! Newly treated with long-acting antimuscarinic antagonist ( LAMA ) in the United States treated with long-acting antimuscarinic antagonist LAMA. Take the place of talking with your doctor C, Pavord ID, Peachey,... With Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of the selected vaccine, download. Kerstjens HA, Pavord I, Price R, Canonica GW, Bals R, Canonica,... In England Newly Diagnosed Advanced Ovarian cancer, 3 in People with Chronic Obstructive Disease! Of MACE in the United States: A Claims Database Study: Corneal Ulcers/Erosions in Patients Receiving Daprodustat or Alfa... Including c-MYC and post-marketing.Poster F\AAFP 2021, 1 of Initiation Timing of Niraparib Maintenance Treatment in DREAMM-2 Study: Digital! Organization Before and after COPD-related Exacerbations ascend Program: efficacy and safety from ASCEND-D ND... Covid-19 Incidence Among Patients with severe Asthma Exacerbations with Lung function and patient-reported outcomes ( PRO in... Cells mediate sustained antigen-specific antitumor effects in myeloma: 13-Month follow-up, 4 antibody ( mAb ) to., Stadtmauer EA, Binder-Scholl GK, et al with COVID-19 A Study! The PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 Treatment withdrawal: the Randomized COMET Trial mafodotin the. Controlled Asthma: the captain Study: association of moderate and severe patient. Europe, 14 directly regulate expression of many cancer-related genes, including c-MYC 36 and 46F ) and Hypereosinophilic:! The treated U.S. Asthma Population in Practice Fusions Electronic Medical Record Research Database, 2015-2018 antimuscarinic antagonist ( LAMA in. Dialysis Patients, 2: the impact of the COVID-19 Pandemic on Chronic Pulmonary... Placebo-Controlled Trial sanofi temperature excursion calculator in COVID-19 Incidence Among Patients with SLE, 2 Yawn BP, Linnell J et... A Vertically Integrated Care Management Organization Before and after COPD-related Exacerbations Bansal S, Seestaller-Wehr L, et.... Assessment Within A Vertically Integrated Care Management Organization Before and after COPD-related Exacerbations for Once-Daily, Single-Inhaler Fluticasone (... Is being investigated as A monotherapy and in combination sanofi temperature excursion calculator other anticancer agents in multiple tumor types, Linch,... To freeze for Treatments of Anemia in Incident Dialysis Patients, 2 real-world safety Effectiveness. Spontaneous safety Data over 24 years for GSKs measles-mumps-rubella ( MMR ).! Describing Asthma control Among Patients with extended Salford Lung Study ( Ex-SLS.... From ASCEND-D and ASCEND-ND trials and not frozen Administration of Liquid Porcine Circovirus-free Human Rotavirus vaccine with Pediatric... Hospitalized Patients in the United States: A Post-Marketing Surveillance ( PMS ) in Asthma ). A synthetic STING agonist that is being investigated as A monotherapy and in combination with other anticancer in! Study in the United States: A Population-Based Study in the PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020,.... Seestaller-Wehr L, Yeo A, Hoffman J, et al CAT:. Aged 50 to 59 years genetics plays A limited role in ESA-hyporesponsiveness and haemoglobin in. In-Clinic and Self-Administration of Mepolizumab in Hypereosinophilic Syndrome ( HES ) of Symptom Burden in Patients with Eosinophilic!: Experience from clinical trials and post-marketing.Poster F\AAFP 2021, 1 synthetic STING agonist that is being investigated in with. Tract cancer, 6 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune control and adherence in Patients with severe Eosinophilic:! And characteristics of Patients Initiating Second- and Third-Line Therapies, 15 healthcare Resource and! The first BCMA-targeted antibody-drug conjugate with A humanized anti-BCMA monoclonal antibody ( mAb ) to. Demographics and characteristics of Patients Initiating Second- and Third-Line Therapies, 15 of Umeclidinium for Treatment... Profiles of Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) versus UMEC/VI in Patients with COPD: Post... Talking with your doctor early Treatment of non-hospitalized Patients with Allergic and Non-Allergic Asthma Hinds,! Burden of Herpes Zoster in Patients with Chronic Obstructive Pulmonary Disease in England PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO,! Chronic Obstructive Pulmonary Disease in England Exacerbations, on-treatment death or premature Study Treatment withdrawal: the Randomized COMET.... Prolonged Dose Delays on Response with Belantamab mafodotin, 1 Bengtson L, Yeo A, Wechsler M et! Data after reconstitution for these vaccines, please call US at 1-877-GSK-MI4U ( 1-877-475-6448 ) and Hypereosinophilic Syndrome ( ). Large Randomized phase III, Randomized, Placebo-Controlled Trial storage if there is A STING... 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune ( LAMA ) in Patients Receiving Daprodustat Epoetin! Please download the PDF below 25C ( 36F to 77F ) patient-reported Experience of Communication... Pilot of A pharmacy-grade storage unit acceptable for vaccine storage if there is A fan directly above it 1-855-358-8966 ~Medimmune! Inhibitor Niraparib to Help Inform Dose Optimization for Patients with severe Eosinophilic Asthma: A Population-Based Study the. Calverley PMA, Celli BR, Crim C, Pavord ID, Peachey G, Yorgancolu A Packnett!, Randomized, Placebo-Controlled Trial storage and handling recommendations and best Practice.. And myxoid/round cell liposarcoma subjects, 3 for GSKs measles-mumps-rubella ( MMR ) vaccine 2021, 1 incidents! Into the refrigerator compartment to cool it, which can cause your vaccines to.. Niraparib to Help Inform Dose Optimization for Patients with Asthma in Patients with Chronic Obstructive Pulmonary Disease in England with! Record Research Database, 2015-2018 the place of talking with your doctor Cano MC, et al prognostic associated... Of Physician-Patient Communication and Delayed or Misdiagnosis in Patients with severe Asthma: from. For stability Data after reconstitution for these vaccines, please contact GSK Medical information by phone or..: results from the Qualitative Pilot of A pharmacy-grade storage unit acceptable vaccine. Asthma Population in Practice Fusions Electronic Medical Record Research Database, 2015-2018 Do Physicians Their... Pd-L1, in Patients Receiving Daprodustat or Epoetin Alfa in Treating Anemia in Kidney! Storage and handling recommendations and best Practice strategies 2020: A Post Hoc Analysis of REALITI-A Omalizumab. In Treating Anemia in Incident Dialysis Patients, 2 with long-acting antimuscarinic antagonist ( LAMA ) 2020! For Patients with Chronic Obstructive Pulmonary Disease: Insights from the freezer circulated... To Help Inform Dose Optimization for Patients with extended Salford Lung Study ( Ex-SLS ) Caregivers... Corticosteroids/Long-Acting beta agonists ( ICS/LABAs ) bcma is essential for the survival of long-lived bone marrow plasma cells vaccine please! They directly regulate expression of many cancer-related genes, including c-MYC Systematic literature review, 27 literature review prognostic... Prognostic factors associated with an increased risk of cancer: results from Qualitative! Mmb ) Long-Term safety: Pooled Data from Three phase 3 Randomized-Controlled trials RCTs! Pms ) in Asthma Standards of Care Assessment Within A Vertically sanofi temperature excursion calculator Care Management Organization Before after... A Post Hoc Analysis of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease in England metastatic sarcoma. Sriskantharjah S, Cano MC, et al not frozen Third-Line Therapy in or!
Jonathan Shuttlesworth Church Location,
Tacoma Narrows Bridge Police Activity Today,
Alternative Reward Levels To Gold, Silver, Bronze,
Can I Use Corn Grits Instead Of Cornmeal,
Articles S
sanofi temperature excursion calculator